These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 7750530)

  • 1. BCG treatment of existing Ta, T1 tumours or carcinoma in situ of the bladder.
    Akaza H
    Eur Urol; 1995; 27 Suppl 1():9-12. PubMed ID: 7750530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
    Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
    Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacillus Calmette-Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group.
    Akaza H; Hinotsu S; Aso Y; Kakizoe T; Koiso K
    Cancer; 1995 Jan; 75(2):552-9. PubMed ID: 7812924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ablative and prophylactic effects of BCG Tokyo 172 strain for intravesical treatment in patients with superficial bladder cancer and carcinoma in situ of the bladder. Bladder cancer BCG Study Group].
    Akaza H; Kameyama S; Kakizoe T; Kojima H; Koiso K; Aso Y; Niijima T
    Nihon Hinyokika Gakkai Zasshi; 1992 Feb; 83(2):183-9. PubMed ID: 1556836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravesical 4'-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer.
    Melekos MD; Chionis HS; Paranychianakis GS; Dauaher HH
    Cancer; 1993 Sep; 72(5):1749-55. PubMed ID: 8348504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Intravesical BCG therapy in patients with recurrent superficial bladder tumors].
    Sugimoto M; Yamamoto H; Itakura H; Shinohara M; Kinoshita K
    Gan To Kagaku Ryoho; 1989 Dec; 16(12):3725-8. PubMed ID: 2596855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical study of prognostic factors of superficial bladder cancer treated with intravesical bacillus Calmette-Guerin.
    Shinka T; Hirano A; Uekado Y; Ohkawa T
    Br J Urol; 1990 Jul; 66(1):35-9. PubMed ID: 2393797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
    Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
    J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
    Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrence of primary superficial bladder cancer treated with prophylactic intravesical Tokyo 172 bacillus Calmette-Guérin: a long-term follow-up.
    Shinka T; Matsumoto M; Ogura H; Hirano A; Ohkawa T
    Int J Urol; 1997 Mar; 4(2):139-43. PubMed ID: 9179686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bacillus Calmette-Guerin intravesical instillation treatment for carcinoma in situ of the bladder. Gifu BCG Instillation Therapy Research Group].
    Nishino Y; Yasuda M; Yokoi S; Ehara H; Yamamoto N; Takahashi Y; Ishihara S; Deguchi T; Kawada Y; Takeda A; Sakai S; Takeuchi T; Taniguchi M; Minoshima K; Hamamoto Y; Kanimoto Y; Nakano M; Fujihiro S; Nezasa S; Matsuda T; Nagatani Y; Maeda S; Tamaki M; Saito A; Komeda H
    Gan To Kagaku Ryoho; 1999 Oct; 26(12):1869-73. PubMed ID: 10560414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guérin for carcinoma in situ of the bladder.
    Merz VW; Marth D; Kraft R; Ackermann DK; Zingg EJ; Studer UE
    Br J Urol; 1995 Feb; 75(2):180-4. PubMed ID: 7850322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).
    Babjuk M; Burger M; Capoun O; Cohen D; Compérat EM; Dominguez Escrig JL; Gontero P; Liedberg F; Masson-Lecomte A; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Seisen T; Soukup V; Sylvester RJ
    Eur Urol; 2022 Jan; 81(1):75-94. PubMed ID: 34511303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Squamous cell carcinoma of bladder after successful intravesical therapy with Bacillus Calmette-Guérin.
    Brenner DW; Yore LM; Schellhammer PF
    Urology; 1989 Aug; 34(2):93-5. PubMed ID: 2763404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of intravesical bacillus Calmette-Guérin therapy with maintenance for urinary bladder carcinoma in situ: About 47 cases.
    Sallami S; Khouni H; Ben Atta M; Abou El Makarim S; Zouari MB; Ben Rhouma S
    Tunis Med; 2016 Dec; 94(12):844. PubMed ID: 28994883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy.
    Cookson MS; Sarosdy MF
    J Urol; 1992 Sep; 148(3):797-801. PubMed ID: 1512829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer.
    Shelley MD; Court JB; Kynaston H; Wilt TJ; Fish RG; Mason M
    Cochrane Database Syst Rev; 2000; 2000(4):CD001986. PubMed ID: 11034738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible factors affecting response to intravesical bacillus Calmette-Guérin (Tokyo 172 strain) therapy for carcinoma in situ of the bladder: a multivariate analysis.
    Takashi M; Katsuno S; Yuba H; Ohshima S; Wakai K; Ohno Y
    Int Urol Nephrol; 1998; 30(6):713-22. PubMed ID: 10195866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.